Recent Finacing
Recent Raise
IsomAb, a 2022 University of Nottingham spinout based in Nottingham BioCity, develops isoform-specific therapeutic antibodies (lead ISM-001 targeting VEGF-A165b) for peripheral ischemia and diabetic vascular disease.
Recent Investors
Total Raised
Funding round
Investors
See the team members at IsomAb.
